Compare FUTU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUTU | BIO |
|---|---|---|
| Founded | 2011 | 1952 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 8.2B |
| IPO Year | 2019 | N/A |
| Metric | FUTU | BIO |
|---|---|---|
| Price | $162.86 | $301.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $208.60 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.3M | 165.1K |
| Earning Date | 11-18-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.17 | N/A |
| EPS | ★ 8.95 | N/A |
| Revenue | $2,442,834,991.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $87.24 | $1.77 |
| Revenue Next Year | $13.85 | $2.30 |
| P/E Ratio | $17.92 | ★ N/A |
| Revenue Growth | ★ 87.15 | N/A |
| 52 Week Low | $70.60 | $211.43 |
| 52 Week High | $202.53 | $373.69 |
| Indicator | FUTU | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 39.83 |
| Support Level | $159.00 | $298.02 |
| Resistance Level | $166.67 | $319.50 |
| Average True Range (ATR) | 5.94 | 8.35 |
| MACD | -0.77 | -2.12 |
| Stochastic Oscillator | 20.62 | 10.28 |
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.